Pharmacoeconomic Evaluation of Wenxin Granules in the Treatment of Cardiovascular Diseases Based on Meta-analysis
10.6039/j.issn.1001-0408.2017.05.04
- VernacularTitle:基于Meta分析的稳心颗粒治疗心血管疾病的药物经济学评价
- Author:
Xiaoyi WANG
;
Ying LU
;
Xiaoyuan FENG
;
Ying WANG
;
Xuan WANG
;
Wentao ZHU
- Keywords:
Wenxin granules;
Cardiovascular disease;
Systematic review;
Pharmacoeconomic
- From:
China Pharmacy
2017;28(5):591-595
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the effectiveness,safety and economy about Wenxin granules in the treatment of cardio-vascular diseases based on Meta-analysis. METHODS:Using“Wenxin granules”“Wenxinkeli”“Wenxin”as the search terms, searching PubMed,ProQuest,Springer,The Cochrane Library,CNKI,VIP and Wanfang data(Jan. 2000-Oct. 2015)through com-puter,relevant journals and conference papers by hand,randomized controlled trials about Wenxin granules in the treatment of car-diovascular diseases were screened and classified according to indications. Meta-analysis was performed by using RevMan 5.3 soft-ware,while cost-effectiveness analysis and minimum cost analysis were used for economic evaluation. RESULTS:Totally,38 liter-atures were involved,including 20 literatures of arhythmia,9 of premature ventricualr contraction,4 of coronary disease angina pectoris,3 of unstable angina pectoris,2 of pediatric viral myocarditis. Meta-analysis showed that compared with control drug, Wenxin granules showed better clinical efficacy for arrhythmia with less ADR;showed better clinical efficacy and ECG efficacy for premature ventricualr contraction with less ADR;showed better clinical efficacy for angina pectoris of coronary disease,unstable angina pectoris and pediatric viral myocarditis,with statistical significance (P<0.05). The incremental cost-effectiveness analysis showed that the additional cost of Wenxin granules in the treatment of above indications was worth it all,compared to control drug. Single factor sensitivity analysis supported the stability of results. CONCLUSIONS:Wenxin granules have a better effectiveness, safety and economy in the treatment of cardiovascular diseases,but still need high-quality evidence to support.
